Madrigal Solidifies Presumed NASH Lead With 52-Week Data

25 Jun 2021

Full-year findings for resmetirom reported at EASL confirm 16-week data in non-alcoholic steatohepatitis presented in 2020. Analysts say these data continue to de-risk the drug, but more important readouts await.

Madrigal office — Madrigal continues to build a solid data rationale behind resmetirom • Source: Madrigal Pharmaceuticals

Fifty-two week data from the first of two Phase III studies of Madrigal Pharmaceuticals, Inc.’s THR beta agonist resmetirom in non-alcoholic steatohepatitis (NASH) confirm earlier results of hepatic fat reduction and suggest improvements in fibrosis and inflammation – the incremental dataset also helps build resmetirom’s chance to be the first approved drug therapy in NASH.

Increased hepatic fat, worsening fibrosis and inflammation are the three hallmark symptoms of the multi-factorial disease, which has been the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Novartis’s Cosentyx Suffers Rare Phase III Fail

03 Jul 2025

• By Kevin Grogan

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: Organon To Pull Plug On OG-6219 Program After Phase II Endometriosis Trial Failure

03 Jul 2025

• By Sushmita Panda

Once hailed as a potential game changer, OG-6219 gets the axe after failing in a Phase II endometriosis-related pain trial.

In Brief: 4DMT Fast-Tracks Long-Acting Wet AMD Therapy Trials, Cuts 25% Of Workforce

03 Jul 2025

• By Sushmita Panda

4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.

In Brief: Atai-Beckley Deal Marches On After Phase II Psychedelic Win

02 Jul 2025

• By Manas Mishra

The psychedelic therapy firms pass a key condition for their planned merger after the antidepressant BPL-003 meets the main endpoints of a Phase IIb trial.

In Brief: Atai-Beckley Deal Marches On After Phase II Psychedelic Win

02 Jul 2025

• By Manas Mishra

The psychedelic therapy firms pass a key condition for their planned merger after the antidepressant BPL-003 meets the main endpoints of a Phase IIb trial.